Evidence map›Paper›PMID 27454288›Full record

ArticleThe Journal of clinical investigation2016

BRCA1 loses the ring but lords over resistance.

Simon N Powell

Abstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Simon N Powell

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
The Response to a Site-Specific Blocked DNA Replication Fork in Human CancersR01CA187069 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI POWELL, SIMON N. · 2014 to 2018
$1.8M
Connections and redundancy in the BRCA1-BRCA2 pathway of homologous recombinationR01CA169306 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI POWELL, SIMON N. · 2013 to 2017
$1.8M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA169306NCI NIH HHS R01 CA187069
6 · The paper itself

Abstract

Germline breast cancer 1 (BRCA1) variants are associated with a high risk of breast and ovarian cancers. Many BRCA1-mediated cancers are initially responsive to platinum-based therapy; however, resistance commonly develops. The BRCA1185delAG mutation is common in the Ashkenazi Jewish population and has been thought to result in loss of function due to the introduction of a stop codon in the 5' region of the BRCA1 transcript. Two studies in this issue of the JCI reveal that the BRCA1185delAG mutation results in the production of BRCA1 that lacks the N-terminal really interesting new gene (RING) domain. RING-less BRCA1 was shown to directly mediate chemoresistance, while maintaining some homologous recombination function. These results provide important insight into BRCA1 function and indicate that other truncated proteins could arise through similar alterations in codon usage.

Indexed as

Genes, BRCA1Breast NeoplasmsFemaleGerm-Line MutationHomologous RecombinationHumansJewsMutationOvarian Neoplasms

Identifiers

PMID27454288
PMCPMC4966308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.